Hudson Bay Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Hudson Bay Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-250,000	Closed	-$39.1M	–	1090
2020 Q4	$39.1M	Buy	+250,000	New	+$32.1M	0.42%	32
2020 Q2	–	Sell	-150,000	Closed	-$13.5M	–	620
2020 Q1	$13.5M	Buy	+150,000	New	+$14.7M	0.34%	50
2019 Q1	–	Sell	-30,000	Closed	-$2.92M	–	978
2018 Q4	$2.92M	Buy	+30,000	New	+$3.55M	0.04%	428
2017 Q4	–	Sell	-60,000	Closed	-$8.42M	–	574
2017 Q3	$8.42M	Sell	60,000 -95,000	-61%	-$12.9M	0.21%	103
2017 Q2	$18.9M	Buy	+155,000	New	+$18M	0.38%	59
2013 Q4	–	Sell	-55,000	Closed	-$6.39M	–	189
2013 Q3	$6.39M	Buy	+55,000	New	+$6.03M	0.24%	85

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Hudson Bay Capital Management's ALXN Position: Q3 2021 in Review

Hudson Bay Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,020,985 shares — an estimated $188M sold.

Hudson Bay Capital Management first reported a position in ALXN in Q3 2013 and held it in 23 quarters. The position peaked at $188M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Hudson Bay Capital Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Hudson Bay Capital Management sold 1,020,985 Alexion Pharmaceuticals shares in Q3 2021, an estimated $188M.
Hudson Bay Capital Management first reported a position in Alexion Pharmaceuticals in Q3 2013 and held it in 23 quarters.
Hudson Bay Capital Management's Alexion Pharmaceuticals position peaked at $188M in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Hudson Bay Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.